Dyne Therapeutics (DYN)
NASDAQ:DYN
Want to see DYN full AI Analyst Report?
Total Valuation
Dyne Therapeutics has a market cap or net worth of $2.86B. The enterprise value is $2.12B.
Market Cap$2.86B
Enterprise Value$2.12B
Share Statistics
Dyne Therapeutics has 165,219,500 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding165,219,500
Owned by Insiders3.90%
Owned by Institutions9.89%
Financial Efficiency
Dyne Therapeutics’s return on equity (ROE) is -0.46 and return on invested capital (ROIC) is -41.02%.
Return on Equity (ROE)-0.46
Return on Assets (ROA)-0.38
Return on Invested Capital (ROIC)-41.02%
Return on Capital Employed (ROCE)-0.41
Revenue Per Employee0.00
Profits Per Employee-2.32M
Employee Count192
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Dyne Therapeutics is ―. Dyne Therapeutics’s PEG ratio is -1.90.
PE Ratio―
PS Ratio0.00
PB Ratio2.58
Price to Fair Value2.58
Price to FCF-6.20
Price to Operating Cash Flow-6.45
PEG Ratio-1.90
Income Statement
In the last 12 months, Dyne Therapeutics had revenue of 0.00 and earned -446.21M in profits. Earnings per share was -3.47.
Revenue0.00
Gross Profit-2.05M
Operating Income-468.18M
Pretax Income-446.21M
Net Income-446.21M
EBITDA-437.97M
Earnings Per Share (EPS)-3.47
Cash Flow
In the last 12 months, operating cash flow was -442.24M and capital expenditures -19.95M, giving a free cash flow of -462.19M billion.
Operating Cash Flow-442.24M
Free Cash Flow-462.19M
Free Cash Flow per Share-2.80
Dividends & Yields
Dyne Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.72
52-Week Price Change48.28%
50-Day Moving Average17.40
200-Day Moving Average16.07
Relative Strength Index (RSI)63.90
Average Volume (3m)2.31M
Important Dates
Dyne Therapeutics upcoming earnings date is Jul 30, 2026, Before Open (Confirmed).
Last Earnings DateMay 11, 2026
Next Earnings DateJul 30, 2026
Ex-Dividend Date―
Financial Position
Dyne Therapeutics as a current ratio of 22.25, with Debt / Equity ratio of 2.23%
Current Ratio22.25
Quick Ratio22.25
Debt to Market Cap<0.01
Net Debt to EBITDA1.99
Interest Coverage Ratio-75.61
Taxes
In the past 12 months, Dyne Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Dyne Therapeutics EV to EBITDA ratio is -3.74, with an EV/FCF ratio of -4.05.
EV to Sales0.00
EV to EBITDA-3.74
EV to Free Cash Flow-4.05
EV to Operating Cash Flow-4.07
Balance Sheet
Dyne Therapeutics has $972.16M in cash and marketable securities with $19.30M in debt, giving a net cash position of $952.85M billion.
Cash & Marketable Securities$972.16M
Total Debt$19.30M
Net Cash$952.85M
Net Cash Per Share$5.77
Tangible Book Value Per Share$7.57
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Dyne Therapeutics is $35.31, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$35.31
Price Target Upside73.03% Upside
Analyst ConsensusStrong Buy
Analyst Count11
Revenue Growth Forecast―
EPS Growth Forecast10.17%